Pooled individual-patient analysis of 11 neoadjuvant early breast cancer RCTs (12,247 patients): distant disease-free survival was a strong trial-level surrogate for overall survival (R2trial 0.91), but weak in hormone receptor-positive subtypes.
Meta-analysisn = 12,247
Conforti et al. Distant disease-free survival as a surrogate endpoint for overall survival in randomised trials of neoadjuvant therapy for early breast cancer: a pooled analysis of GBG and AGO-B Study Group trials